## 505802613 12/04/2019

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5849442

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date	
JPHARMA SOLUTIONS GMBH	09/10/2019	

## **RECEIVING PARTY DATA**

Name:	APELLIS PHARMACEUTICALS, INC.	
Street Address:	6400 WESTWIND WAY	
Internal Address:	SUITE A	
City:	CRESTWOOD	
State/Country:	KENTUCKY	
Postal Code:	40014	

## **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	16500994

#### **CORRESPONDENCE DATA**

**Fax Number:** (617)502-5002

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 6172485000

**Email:** patentdocket@choate.com

Correspondent Name: CHOATE HALL & STEWART LLP Address Line 1: TWO INTERNATIONAL PLACE

Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	2008575-0384
NAME OF SUBMITTER:	SOWMYA SUBRAMANIAN, PHD
SIGNATURE:	/Sowmya Subramanian/
DATE SIGNED:	12/04/2019

## **Total Attachments: 5**

source=2008575-0384 Confirmatory Assignment (JPharma to Apellis)#page1.tif source=2008575-0384 Confirmatory Assignment (JPharma to Apellis)#page2.tif source=2008575-0384 Confirmatory Assignment (JPharma to Apellis)#page3.tif source=2008575-0384 Confirmatory Assignment (JPharma to Apellis)#page4.tif source=2008575-0384 Confirmatory Assignment (JPharma to Apellis)#page5.tif

PATENT 505802613 REEL: 051174 FRAME: 0817

# **CONFIRMATORY ASSIGNMENT**

WHEREAS, JPharma Solutions GmbH, (hereinafter "ASSIGNOR") a corporation having a usual place of business at Eichenweg 9, Bülach, CH-8180, Switzerland, is the owner by assignment of patent(s), patent application(s) and the invention(s) listed on Schedule A, including the rights in and to any provisionals, continuations, divisionals, reissues, reexaminations, or other filings claiming priority thereto, the corresponding foreign patent applications and foreign patents arising out of the aforementioned patent(s) and patent application(s), any future patents related thereto, in whole or in part, or issuing therefrom, and the inventions described and/or claimed in said patent(s) and patent application(s) (referred to collectively hereinafter as the "PATENT RIGHTS"), and

WHEREAS Apellis Pharmaceuticals, Inc. (hereinafter "ASSIGNEE"), a corporation organized and existing under the laws of the State of Delaware, and having a usual place of business at 6400 Westwind Way, Suite A, Crestwood, Kentucky 40014, desires to acquire the entire right, title and interest therein, in accordance with agreements entered into with ASSIGNEE;

WHEREAS, ASSIGNOR and ASSIGNEE have entered into a certain Consulting Agreement, dated as of March 3, 2014, pursuant to which ASSIGNOR assigned to ASSIGNEE all of ASSIGNOR's right, title, and interest in and to ASSIGNOR's intellectual property including, without limitation, the PATENT RIGHTS;

NOW, THEREFORE, to all whom it may concern be it known that, for good and valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged, ASSIGNOR has sold, assigned, and transferred and by these presents does hereby confirm its sale, assignment, and transfer unto ASSIGNEE, its successors, assigns, and legal representatives, ASSIGNOR'S entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to the inventions described and/or claimed in said PATENT RIGHTS, together with ASSIGNOR's entire right, title and interest in and to the patent(s) and patent application(s) listed on Schedule A and such other patents as may issue thereon or claim priority under United States law or international convention, including but not limited to non-provisionals, continuations, divisionals, reissues, reexaminations, extensions, and substitutions of said patent(s) and patent application(s), and any right, title and interest ASSIGNOR may have in provisional applications to which said PATENT RIGHTS claim priority; said invention(s), application(s) and patent(s) to be held and enjoyed by ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by ASSIGNOR had this assignment and sale not been made; ASSIGNOR hereby conveys all of its rights arising under or pursuant to any and all United States laws and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for patent, including but not limited to any cause(s) of action and damages accruing prior to this assignment;

Page 1 of 5

8707557v1 Attorney Docket: 2008575-0280

AND, ASSIGNOR hereby acknowledges that this assignment, being of its entire right, title and interest in and to said invention(s), application(s) and patent(s), carries with it the right in ASSIGNEE to apply for an obtain from competent authorities in all countries of the world any and all patents by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all patents to ASSIGNEE in its own name as assignee of ASSIGNOR's entire right, title and interest therein;

AND, ASSIGNOR hereby further agrees for itself and its successors, assigns, agents, and legal representatives to provide statements or testimony in any interference or proceeding in which said patent(s) or patent application(s) or invention(s) directed thereto may be involved; to communicate to ASSIGNEE, its successors, assigns and legal representatives, any facts known to ASSIGNOR regarding said invention(s), and to testify in any legal proceedings, sign all lawful papers, make all rightful oaths, and generally execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid inventions to ASSIGNEE, its successors, assignees, and legal representatives, including the execution of non-provisional, substitution, continuation, divisional, reissue, reexamination, or corresponding foreign or international patent applications, and generally do everything possible to aid ASSIGNEE, its successors, assigns and legal representatives, to obtain, record and enforce full protection for the invention(s) in all countries, but in each instance at ASSIGNEE's reasonable expense;

AND, ASSIGNOR does hereby authorize and request the Director of the United States Patent and Trademark Office and any officials of any country or counties other than the United States, whose duty is to issue patents or other forms of industrial property protection, to issue the same as shall be granted upon any application relating to said PATENT RIGHTS to ASSIGNEE, its successors, assigns, or legal representatives;

AND, ASSIGNOR covenants and agrees that it has full right to convey the entire right, title, and interest assigned, and it has not executed and will not execute any agreement in conflict herewith;

IN TESTIMONY WHEREOF, ASSIGNOR and ASSIGNEE by their duly authorized representative acting on their own free will have caused this instrument to be duly executed and have hereunto set his hand and affixed our seal on the dates set forth below.

The undersigned (whose title is supplied below) is authorized to ac JPharma Solutions CophH		alf of
Signature: / 2	Date:	105573019
Name (printed) - Partie 1822 - Emiliana		ti kama
THE Control Care Control Still		

Page 3 of 5

8707557y1

Attorney Docket: 2008575-0280

The undersigned (whose title is supplied below) is authorized to ac	et on ber	all of
Apellis Pharmaceuticals, Inc.		
Signature:	Date:	Accust 28,2019
Name (printed): DAVID O. Watson		
Title (printed): Secretary		

# SCHEDULE A

Application No. Filing Date	Title	Patent No.	Issue	
Application No. Filing Date			(if applicable)	Date
62/483295	April 7, 2017	DOSING REGIMENS AND		
		RELATED COMPOSITIONS		
		AND METHODS		
62/485343	April 13, 2017	DOSING REGIMENS AND		
		RELATED COMPOSITIONS		
		AND METHODS		
PCT/US18/26753	April 9, 2018	DOSING REGIMENS AND		
		RELATED COMPOSITIONS		
		AND METHODS		

Page 5 of 5

8707557v1 Attorney Docket: 2008575-0280

**PATENT** 

RECORDED: 12/04/2019 REEL: 051174 FRAME: 0822